ERBB2 and breast cancer: In phase II clinical trials, trastuzumab-DM1 monotherapy showed similar success compared to other HER2 therapies in HER2-positive breast cancer (Table 1) and was well-tolerated with only ~20% of patients experiencing adverse effects [53].